In a bad news, good news story, specialists from around the world are reporting Parkinson’s disease patients are displaying new creative talents — presumably as an offshoot of medications for their condition.
Medical therapy for Parkinson’s disease includes drugs that increase the activity of dopamine in the brain to reduce tremors and muscle rigidity. Apparently these medications are having an unintentional creative side effect, enhancing an individual’s artistic talents including painting, sculpting, writing, and more.
Prof. Rivka Inzelberg, M.D., of Tel Aviv University’s Sackler Faculty of Medicine first noticed the trend in her own Sheba Medical Center clinic when the usual holiday presents from patients — typically chocolates or similar gifts — took a surprising turn.
“Instead, patients starting bringing us art they had made themselves,” she said.
Inspired by the discovery, Inzelberg sought out evidence of this rise in creativity in current medical literature.
Bringing together case studies from around the world, she examined the details of each patient to uncover a common underlying factor — all were being treated with either synthetic precursors of dopamine or dopamine receptor agonists. These drug regimens increase the amount of dopamine activity in the brain by stimulating receptors.
Dopamine is involved in several neurological systems, Inzelberg said.
Its main purpose is to aid in the transmission of motor commands, which is why a lack of dopamine in Parkinson’s patients is associated with tremors and a difficulty in coordinating their movements.
However, dopamine is also involved in the brain’s “reward system” — the satisfaction or happiness we experience from an accomplishment.
Inzelberg believes this component of dopamine’s action is associated with increasing creativity.
Dopamine and artistry have long been connected, she said, citing the example of 19th century painter Vincent Van Gogh, who suffered from psychosis.
It’s possible that his creativity was the result of this psychosis, thought to be caused by a spontaneous spiking of dopamine levels in the brain.
There are seemingly no limits to the types of artistic work for which patients develop talents, Inzelberg said.
Cases include an architect who began to draw and paint human figures after treatment, and a patient who, after treatment, became a prize-winning poet though he had never been involved in the arts before.
It’s possible that these patients are expressing latent talents they never had the courage to demonstrate before, she said.
Dopamine-inducing therapies are also connected to a loss of impulse control, and sometimes result in behaviors like excessive gambling or obsessional hobbies. An increase in artistic drive could be linked to this lowering of inhibitions, allowing patients to embrace their creativity.
Some patients have even reported a connection between their artistic sensibilities and medication dose, noting that they feel they can create more freely when the dose is higher.
Inzelberg believes the artistic expressions can be used in a therapeutic manner, both psychologically and physiologically. Her patients report being happier when they are busy with their art, and have noted that motor handicaps can lessen significantly.
One such patient is usually wheelchair-bound or dependent on a walker, but creates intricate wooden sculptures that have been displayed in galleries.
External stimuli can sometimes bypass motor issues and foster normal movement, she explains. Similar types of art therapy are already used for dementia and stroke patients to help mitigate the loss of verbal communication skills, for example.
The next step is to try to characterize those patients who become more creative through treatment through comparing them to patients who do not experience a growth in artistic output.
“We want to screen patients under treatment for creativity and impulsivity to see if we can identify what is unique in those who do become more creative,” said Inzelberg. She also believes that such research could provide valuable insights into creativity in healthy populations, too.
Her report will be published in the journal Behavioral Neuroscience.